Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | MAP2K1 C121S MAP2K1 P124R |
Therapy | Trametinib |
Indication/Tumor Type | melanoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MAP2K1 C121S MAP2K1 P124R | melanoma | predicted - sensitive | Trametinib | Case Reports/Case Series | Actionable | In a clinical case study, Mekinist (trametinib) resulted in a partial response after two months of treatment in a patient with melanoma harboring MAP2K1 C121S and MAP2K1 P124R (PMID: 36901951). | 36901951 |
PubMed Id | Reference Title | Details |
---|---|---|
(36901951) | Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma. | Full reference... |